Novartis Famvir detailing
Executive Summary
Novartis doubles call rate for genital herpes therapy Famvir (famciclovir) following Zelnorm and Xolair delays. "It was just a transfer from one division to another," Pharmaceuticals CEO Paulo Costa says. Novartis also "upped" the effort behind anti-hypertensives Diovan and Lotrel. "With Diovan, we have about 2 mil. primary details or primary equivalents, and with Lotrel, we have about 1.7 mil. So, it's a very significant effort"